%0 Journal Article
%T Comparing Treatment Modalities for End-Stage Renal Disease: A Meta-Analysis
%A Ellen S. Campbell
%A Gilbert L. Queeley
%J Archive of "American Health & Drug Benefits".
%D 2018
%X End-stage renal disease (ESRD) imposes significant economic and social burdens on patients and healthcare systems. In the United States alone, more than 600,000 Americans have ESRD, with an estimated annual cost of treatment of more than $30 billion. Peritoneal dialysis and hemodialysis are competing renal replacement therapies in ESRD; however, data comparing quality-of-life outcomes between these 2 modalities are limited
%K end-stage renal disease
%K health-related quality of life
%K hemodialysis
%K peritoneal dialysis
%K random-effects model
%K subgroup analysis
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973249/